Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s UI/release version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3” without changing the study details shown.
    Difference
    0.0%
    Check dated 2026-04-26T15:30:03.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-19T13:49:47.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    38 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.4.3 to v3.5.0. This change does not affect core study details or patient-facing information.
    Difference
    0.0%
    Check dated 2026-03-21T17:12:38.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added and Revision: v3.4.2 was removed.
    Difference
    0.0%
    Check dated 2026-03-07T06:46:05.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Revision updated to v3.4.2, replacing the previous v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-13T17:39:46.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    The change is limited to a revision number update from v3.4.0 to v3.4.1; no study content or functionality appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T11:32:15.000Z thumbnail image

Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.